Medical Pharmacology: Pulmonary Pharmacology Practice Questions
Choose the correct answer for each question.
Drug(s) that may be useful in treating pulmonary hypertension (PAH):
Prostacyclin
Prostacyclin analogs
Both
Neither
Drug class/classes that may be useful in treating pulmonary hypertension:
Phosphodiesterase-5 inhibitors
A guanylyl cyclase stimulator
Endothelin receptor blockers
A & B
B & C
A & C
A, B & C
Concerning pulmonary hypertension:
Platelet activation and endothelial dysfunction in PAH induce decreases in prostacyclin levels and increases in thromboxane A2 production.
Prostacyclin (PGI2) promotes vasodilation through activation of cAMP requiring pathways.
Prostacyclin synthase levels are increased in pulmonary arteries of patients exhibiting pulmonary hypertension.
A & B
B & C
A & C
A, B & C
Imbalance of mediators important in pulmonary artery pathologies associated with pulmonary artery hypertension can be managed by administration of prostanoids.
True
False
First prostanoid available for management of pulmonary hypertension:
Treprostinil (Remodulin; Tyvaso)
Epoprostenol (Flolan; Veletri)
Continuous IV infusion of epoprostenol:
Improved pulmonary hypertension survival
Improved functional capacity
Both
Neither
Characteristic(s) of the treprostinil compared to epoprostenol:
Treprostinil exhibits a shorter half-life
Treprostinil can be administered by continuous subcutaneous in IV administration.
Both
Neither
Inhaled Prostacyclins:
Comparable beneficial effects compared with infused prostacyclin treatment.
Elimination ofside effects associated with infusion catheters
Both
Neither
Examples/example of Prostacyclins approved for treating pulmonary hypertension:
Trepostinil
Iloprost (Ventavis)
Both
Neither
Adding a PDE5 (phosphodiesterase-5) inhibitor to a regimen including an inhaled prostacyclin can result in which one(s) of the following?
Improved pulmonary hemodynamics compared to prostanoids alone.
Improved pulmonary functional capacity available with prostanoids alone
